Literature DB >> 19925027

Optimization of a new non-viral vector for transfection: Eudragit nanoparticles for the delivery of a DNA plasmid.

M Gargouri1, A Sapin, S Bouli, P Becuwe, J L Merlin, P Maincent.   

Abstract

The development of new vectors to deliver DNA into cells for therapy of cancers or genetic diseases has been a major area of research for many years. However, the clinical application of this technology requires the development of efficient, reliable and sterile vectors enabling the transfer of genes in vivo. Non viral, polymer or lipid-based vectors offer a new impetus to gene therapy because they are less toxic than viral vectors (no endogenous recombination, fewer immunological reactions, easy production and delivery of large-sized plasmid). The aim of this study is to develop a new tool for DNA delivery composed of methacrylic polymeric (Eudragit RS and RL) nanoparticles. These nanoparticles were prepared by two methods: nanoprecipitation and double emulsion. The nanoparticles were characterized by their size, zeta potential and amount of DNA adsorption. Cytotoxicity tests based on mitochondrial activity (MTT test) revealed that the nanoparticles had limited cytotoxicity and that this depended on both the cell type and the nanoparticle concentration. Transgene expression was observed using the Green Fluorescence Protein gene as reporter gene, and was evaluated by flow cytometry in FaDu, MDA-MB 231 and MCF-7 cell lines. The results showed that transfection rates ranging between 4 and 7% were achieved in FaDu and MDA-MB 231 cells with nanoparticles prepared by the nanoprecipitation method. In MCF-7 cells transfected with nanoparticles prepared by either the double emulsion or the nanoprecipitation method, the transfection efficiency was between 2 and 4%. Nanoparticles prepared by nanoprecipitation were slightly more efficient than nanoparticles prepared from a double emulsion. Particle size was not an important factor for transfection, since no significant difference was observed with size between 50 and 350 nm. We showed that Eudragit RS and RL nanoparticles could introduce the transgene into different types of cells, but were generally less effective than the lipofectamine control.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19925027     DOI: 10.1177/153303460900800605

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  4 in total

1.  Cationic nanomicelles for delivery of plasmids encoding interleukin-4 and interleukin-10 for prevention of autoimmune diabetes in mice.

Authors:  Rhishikesh Mandke; Jagdish Singh
Journal:  Pharm Res       Date:  2011-11-11       Impact factor: 4.200

Review 2.  Engineered nanoparticulate drug delivery systems: the next frontier for oral administration?

Authors:  Roudayna Diab; Chiraz Jaafar-Maalej; Hatem Fessi; Philippe Maincent
Journal:  AAPS J       Date:  2012-07-06       Impact factor: 4.009

3.  Finding key nanoprecipitation variables for achieving uniform polymeric nanoparticles using neurofuzzy logic technology.

Authors:  Miguel O Jara; Johanna Catalan-Figueroa; Mariana Landin; Javier O Morales
Journal:  Drug Deliv Transl Res       Date:  2018-12       Impact factor: 4.617

4.  Uptake of Eudragit Retard L (Eudragit® RL) Nanoparticles by Human THP-1 Cell Line and Its Effects on Hematology and Erythrocyte Damage in Rats.

Authors:  Mosaad A Abdel-Wahhab; Khaled G Abdel-Wahhab; Fathia A Mannaa; Nabila S Hassan; Ramia Safar; Roudayna Diab; Bernard Foliguet; Luc Ferrari; Bertrand H Rihn
Journal:  Materials (Basel)       Date:  2014-02-28       Impact factor: 3.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.